<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216047</url>
  </required_header>
  <id_info>
    <org_study_id>HOG BRE04-80</org_study_id>
    <nct_id>NCT00216047</nct_id>
  </id_info>
  <brief_title>PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of&#xD;
      HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in&#xD;
      HER2-overexpressing breast cancers may contribute to the aggressive phenotype observed in&#xD;
      HER2-positive breast cancer. New therapeutics targeting VEGF and/or its receptors may enhance&#xD;
      the efficacy of trastuzumab monotherapy.&#xD;
&#xD;
      This trial will investigate the safety and efficacy of combined HER2 and VEGF inhibition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
      PTK787 daily plus trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease&#xD;
      evaluation every other cycle.&#xD;
&#xD;
      Patients may continue treatment until disease progression or toxicity intervenes.&#xD;
&#xD;
      Performance Status: ECOG 0 or 1&#xD;
&#xD;
      Life Expectancy: Not specified&#xD;
&#xD;
      Hematopoietic:&#xD;
&#xD;
        -  ANC &gt; 1500 mm3&#xD;
&#xD;
        -  Platelets &gt; 100,000 mm3&#xD;
&#xD;
        -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
        -  PTT and INR &lt; 1.5 x ULN&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  ALT and AST &lt; 3 x ULN (&lt; 5 x ULN in patients with known liver metastases)&#xD;
&#xD;
        -  Alkaline phosphatase &lt; 2.5 x ULN&#xD;
&#xD;
        -  Serum bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
      Renal:&#xD;
&#xD;
        -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
        -  Proteinuria &lt; 1+ by dipstick OR total urinary protein &lt; 500 mg/24 hours with measured&#xD;
           creatinine clearance (CrCl) â‰¥ 50 mL/min&#xD;
&#xD;
      Cardiovascular:&#xD;
&#xD;
        -  No clinically significant cardiac disease (e.g. congestive heart failure, symptomatic&#xD;
           coronary artery disease and cardiac arrhythmias not well controlled with medication) or&#xD;
           myocardial infarction within the last 6 months.&#xD;
&#xD;
        -  LVEF &gt; LLN by MUGA or ECHO (obtained within 28 days prior to being registered for&#xD;
           protocol therapy)&#xD;
&#xD;
      Pulmonary:&#xD;
&#xD;
        -  Not specified&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low patient enrollment; toxicities&#xD;
  </why_stopped>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Cohorts:</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary objective is to ensure the safety and tolerability of the combination of Trastuzumab and PTK787,</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II Cohorts:</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess response rate of PTK787 combined with trastuzumab in patients with newly diagnosed HER2 overexpressing</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II Cohorts:</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of PTK787 combined with trastuzumab</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the time to progression and clinical benefit of PTK787 combined with trastuzumab</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single Group Assignment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab + PTK787 for HER2 positive patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTK787</intervention_name>
    <description>PTK787 daily</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle*</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of breast cancer with evidence of measurable (1)&#xD;
             unresectable, locally recurrent, or (2) metastatic disease. Locally recurrent disease&#xD;
             must not be amenable to resection OR radiation with curative intent.&#xD;
&#xD;
          -  Patient's disease may not involve more than 3 metastatic sites. In addition, patient&#xD;
             may not be symptomatic from pulmonary metastasis or have liver metastasis involving &gt;&#xD;
             50% of parenchyma.&#xD;
&#xD;
          -  HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry&#xD;
             will not be sufficient for entry.&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy or trastuzumab for locally recurrent or metastatic&#xD;
             disease.&#xD;
&#xD;
          -  No prior treatment with any VEGF inhibiting agents&#xD;
&#xD;
          -  No history or presence of central nervous system (CNS) disease.&#xD;
&#xD;
          -  No other forms of cancer therapy including radiation, chemotherapy and hormonal&#xD;
             therapy within 21 days prior to being registered for protocol therapy.&#xD;
&#xD;
          -  No major surgery within 28 days prior to being registered for protocol therapy.&#xD;
&#xD;
          -  No uncontrolled hypertension (SBP &gt; 170, DBP &gt; 90), history of labile hypertension or&#xD;
             history of poor compliance with antihypertensive therapy.&#xD;
&#xD;
          -  No requirement for therapeutic anticoagulation, regular aspirin (&gt; 325 mg/day) or&#xD;
             NSAID use.&#xD;
&#xD;
          -  No current breast feeding.&#xD;
&#xD;
          -  No impairment of gastrointestinal (GI) function that may significantly alter the&#xD;
             absorption of PTK787.&#xD;
&#xD;
          -  No evidence of other serious concomitant systemic disorders incompatible with the&#xD;
             study (at the discretion of the investigator).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Miller, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elkhart Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care at Goshen Health System</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46527</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, P.C.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hoosieroncologygroup.org/</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Kathy Miller, MD</investigator_full_name>
    <investigator_title>Professor, IU School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

